NVAXNovavax, Inc.
$9.69+14% 1Y
$9.69
$6.2252 weeks$12.83
Is the price fair?
What NVAX's price assumes
Novavax, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 3.86× revenue.
3.86
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 2.83
EV / sales
Details›
- EV / EBIToperating margin −57%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 2.83
- Market capitalisation164.9 million shares, counted Jul 31, 2026
- $1.60B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks